A61L27/367

Compositions for Regenerating Defective or Absent Myocardium
20180177923 · 2018-06-28 ·

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Compositions and Methods for Treatment of Cardiovascular Disorders
20180147241 · 2018-05-31 ·

Methods for treating cardiovascular disorders that include administration of an ECM based composition to damaged cardiovascular tissue in conjunction with a treatment remedy, such as ventricular assistance and transmyocardial revascularization (TMR), which induces enhanced bioremodeling of the damaged cardiovascular tissue and regeneration of new cardiovascular tissue and associated structures with site-specific structural and functional properties.

Cellular seeding and co-culture of a three dimensional fibroblast construct

The present invention provides methods for cellular seeding onto three-dimensional fibroblast constructs, three-dimensional fibroblast constructs seeded with muscle cells, and uses therefore.

Compositions and Methods for Treatment of Cardiovascular Disorders
20180125896 · 2018-05-10 ·

ECM based compositions including amniotic membrane and methods for employing same to treat cardiovascular disorders.

Layered cell sheets containing myoblasts and method for producing same

Provided are layered cell sheets, comprising a plurality of layered cell sheets containing myoblasts, in which each cell sheet comprises cell population containing myoblasts with controlled orientations. Preferably provided are the layered cell sheets comprising a region in which the orientations of the cell population containing the myoblasts in each cell sheet are identical to each other.

DECELLULARIZED MUSCLE MATRIX
20240390554 · 2024-11-28 ·

Disclosed herein are muscle implants and methods of making muscle implants comprising one or more decellularized muscle matrices. The muscle matrices can be provided in a particulate form suitable for injection or implantation.

DECELLULARIZED MUSCLE MATRIX
20240366364 · 2024-11-07 ·

Disclosed herein are muscle implants and methods of making muscle implants comprising one or more decellularized muscle matrices. The muscle matrices can, optionally, be joined to one or more decellularized dermal matrices. The muscle implants can be used to enhance muscle volume or to treat muscle damage, defects, and/or disorders. The decellularized muscle matrices in the implants retain at least some of the myofibers found in a muscle tissue prior to processing.

Prosthetic tissue valves and methods for anchoring same to cardiovascular structures
09907649 · 2018-03-06 · ·

A prosthetic atrioventricular tissue valve comprising a continuous tubular member formed from a first biocompatible material, the tubular member having proximal and distal ends, and at least one valve leaflet formed therein, the distal end of the tubular member including cardiovascular structure engagement means for connecting the tubular member to a cardiovascular structure, the cardiovascular structure engagement means comprising a plurality of elongated members that extend distally from the distal end of the tubular member.

Tissue Use for Repair of Injury
20180055622 · 2018-03-01 ·

The present disclosure describes methods of treating an injury in a subject using placental tissue streamers, engineered tissue placental tissue hybrids, suture placental tissue hybrids, placental tissue patch hybrids, and tissue hybrids, and the use of these compositions to repair, treat, or support an injury or degenerative process in a subject.

DELIVERY OF PARTICLES USING HYGROSCOPIC EXCIPIENTS
20180043585 · 2018-02-15 ·

A method of delivering a therapeutic agent comprises providing an aerosol generator that produces an aerosol of particles or droplets containing a therapeutic agent and an excipient for delivery to a first portion of a respiratory tract. The particles or droplets have an initial diameter from about 1 m to about 8 m, and the initial momentum of the particles or droplets minimizes deposition in the first portion. The particles or droplets are exposed to relative humidity in the respiratory tract by delivering them at a flow rate that defines the residence time in the respiratory tract. The particles or droplets increase in diameter due to hygroscopic growth caused by relative humidity. The aerosol is nasally exhaled so that particles or droplets are delivered to the nasal cavity and deposited in the nasal turbinates or sinus in part because of their increased diameter.